February 21, 2017 07:14 AM EST
Pharma

Gilead bags Sarep­ta's pri­or­i­ty re­view vouch­er for a dis­count, pay­ing $125M

John Carroll

Editor & Founder

Back in the sum­mer of 2015, Ab­b­Vie agreed to pay $350 mil­lion for a pri­or­i­ty re­view vouch­er, which can be used to shave four months …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times